Outcome of the Board Meeting held on Thursday, May 21, 2026

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionRelated-party transactionsDebt to equity above the thresholdResults View source PDF Explain this filing

NGLFINE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+10.9%Reaction day

₹2525.00

prior close

₹2569.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+10.8% vs market

Pharmaceuticals peers, median of 164sector-0.1%+11.0% vs sector

On the reaction day the stock moved 10.8 pts more than Nifty Microcap 250 and 11.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.4

10m

-5.8

15m

-10.2

30m

-9.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+10.9+0.1+10.8-0.1+11.0

Next day

+12.7+1.7+11.0+0.9+11.8

+10.9+2.4+8.5+0.9+10.1

+4.4+2.4+2.0+0.7+3.7

+10.9+1.7+9.2+0.8+10.1

+9.2+0.6+8.6+0.0+9.2

+5.0+1.9+3.0-0.1+5.0

15d

+24.8+4.9+19.9+1.0+23.7

+24.2+8.9+15.2+3.0+21.2

+29.0+7.5+21.5+4.4+24.6

+13.9+13.6+0.3+7.9+6.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

NGL Fine Chem reported strong FY2026 results. Consolidated revenue grew 36% to ₹50,095.47 lakhs from ₹36,825.67 lakhs in FY2025. Net profit (PAT) surged 128% to ₹4,812.67 lakhs from ₹2,112.43 lakhs. EBITDA expanded significantly to ₹6,336.77 lakhs (vs ₹2,771.42 lakhs prior year). The board recommended a final dividend of ₹1.75 per share (₹108.12 lakhs total). Statutory auditors M/s Manek & Associates issued an Unmodified Opinion. The company appointed KD Practice Consulting Pvt. Ltd. as Internal Auditors and Sanghavi Randeria & Associates as Cost Auditor for FY2026-27. Mr. Rajesh Lawande was reappointed as Whole-Time Director (related to Mrs. Ajita Nachane, sister), and Mrs. Sarala Menon was reappointed as Independent Director, both subject to shareholder approval at the August 2026 AGM.

Likely market impact

Exceptional financial year with near-doubling of PAT and 36% revenue growth. Unmodified auditor opinion signals clean financials. Dividend payout signals management confidence. However, non-current borrowings doubled to ₹5,640.33 lakhs (from ₹2,533.56 lakhs), indicating higher leverage. Related party appointment of Mr. Rajesh Lawande should be monitored.